Calidi Biotherapeutics, Inc. has 8 Schedule 13D or 13G filings on record since 2025-08-14. No holder's latest filing reports 5% or more. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Armistice Capital, LLC | 4.99% | 63,391 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| Gavrilov Ognian Anguelov | 0.3% | 20,000 | SCHEDULE 13D, 2026-03-31 | 2026-03-31 |
| Lincoln Alternative Strategies LLC | 0% | 0 | SCHEDULE 13G/A, 2026-02-10 | 2025-09-18 |
Purpose of Transaction (Item 4)
Gavrilov Ognian Anguelov
The Reporting Person has effected dispositions of Shares as described in Item 5, resulting in beneficial ownership of approximately 0.3% of the outstanding Shares. The Reporting Person does not currently have any plans or proposals that relate to or would result in any of the actions described in Item 4 of Schedule 13D. However, the Reporting Person may, from time to time, acquire or dispose of securities of the Issuer in the open market or otherwise, depending on market conditions and other factors.Item 4 of the SCHEDULE 13D filed 2026-03-31
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-14 | Armistice Capital, LLC | 4.99% | SCHEDULE 13G/A |
| 2025-08-27 | Lincoln Alternative Strategies LLC | 14.46% | SCHEDULE 13G |
| 2026-02-04 | Gavrilov Ognian Anguelov | 7.8% | SCHEDULE 13G |
| 2026-02-10 | Lincoln Alternative Strategies LLC | 0% | SCHEDULE 13G/A |
| 2026-03-09 | Gavrilov Ognian Anguelov | 9.8% | SCHEDULE 13D |
| 2026-03-31 | Gavrilov Ognian Anguelov | 0.3% | SCHEDULE 13D |
| 2026-05-15 | Armistice Capital, LLC | 9.99% | SCHEDULE 13G |
| 2026-08-14 | Armistice Capital, LLC | 4.99% | SCHEDULE 13G/A |
Tools for this story
Each opens in a new tab, filled in for Calidi Biotherapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.